This is a Phase II/Phase III study of intravesical AD 32 (valrubicin) in patients with
carcinoma in situ (CIS) who have been previously treated with intravesical Bacillus
Calmette-Guerin (BCG) for CIS and in whom recurrence or failure has occurred after multiple
courses of intravesical treatment.
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Stacy Childs, MD, Alabaster, Alabama, United States
William Bohnert, MD, Phoenix, Arizona, United States
Scott Swanson, MD, Scottsdale, Arizona, United States
Bruce Dalkin, MD, Tucson, Arizona, United States
Donald Gleason, MD, Tucson, Arizona, United States
William Friedel, MD, La Mesa, California, United States
Stephen Auerbach, MD, Newport Beach, California, United States
William Moseley, MD, San Diego, California, United States
Standley Brosman, MD, Santa Monica, California, United States
Eugene Dula, MD, Van Nuys, California, United States
B. Thomas Brown, MD, Daytona Beach, Florida, United States
Charles Jackson, MD, Ft. Lauderdale, Florida, United States
Marc Soloway, MD, Miami, Florida, United States
Charles Brendler, MD, Chicago, Illinois, United States
Patrick Guinan, MD, Chicago, Illinois, United States
Jeffrey Ignatoff, MD, Evanston, Illinois, United States
David Wood, MD, Lexington, Kentucky, United States
John Tuttle, MD, Lexington, Kentucky, United States
Dennis Venable, MD, Shreveport, Louisiana, United States
Harold Frazier, MD, Bethasda, Maryland, United States
Myron Murdock, MD, Greenbelt, Maryland, United States
John Libertino, Burlington, Massachusetts, United States
W. Lamar Weems, MD, Jackson, Mississippi, United States
Hugh Fisher, MD, Albany, New York, United States
Michael Blute, MD, Rochester, New York, United States
Michael Wolff, MD, Burlington, North Carolina, United States
Cary Robertson, MD, Durham, North Carolina, United States
Eric Klein, MD, Cleveland, Ohio, United States
Bruce Lowe, MD, Portland, Oregon, United States
Jeffrey Cohen, MD, Pittsburgh, Pennsylvania, United States
Jacques Susset, MD, Providence, Rhode Island, United States
L. Dean Knoll, MD, Nashville, Tennessee, United States
Steohen Hardeman, MD, Austin, Texas, United States
Ian Thompson, MD, Ft. San Houston, Texas, United States
Seth Lemer, MD, Houston, Texas, United States
Aaron Katz, MD, Richmond, Virginia, United States
Gary Katz, MD, Richmond, Virginia, United States
Williams Ellis, MD, Seattle, Washington, United States
Richard Boxer, MD, Milwaukee, Wisconsin, United States
Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000 Mar;163(3):761-7. Erratum in: J Urol. 2008 Jan;179(1):386.